WINT - WINDTREE THERAPEUTICS INC /DE/
IEX Last Trade
0.3113
0.008 2.538%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:28:31 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$0.30
0.01
2.60%
Fundamental analysis
6%
Profitability
1%
Dept financing
22%
Liquidity
35%
Performance
0%
Performance
5 Days
-5.12%
1 Month
-45.41%
3 Months
-89.52%
6 Months
-90.82%
1 Year
-58.38%
2 Year
-96.27%
Key data
Stock price
$0.31
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.32 - $14.75
52 WEEK CHANGE
-$58.38
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Craig E. Fraser
Region: US
Website: windtreetx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: windtreetx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Windtree Therapeutics, Inc. focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trials for heart failure, and AEROSURF, an aerosolized KL4 surfactant.
Recent news